At #ASH24, Fnu Amisha, MD discussed predictive markers for outcomes after disease progression post BCMA-directed CAR T-cell therapy in patients with relapsed or refractory multiple myeloma (RRMM).
➡️The prognosis of RRMM who develop progressive disease post-BCMA CAR T-cell therapy is poor.
➡️ High-risk cytogenetics and high tumor burden at the time of progression are associated with worse outcomes in these patients.
➡️ The post progression use of either BCMA or GPRC5D bispecific antibody is associated with improved outcomes as compared to combination therapy.
Read more: [ Ссылка ]
